Open Veils · Answer
Vyvanse compared to generic versions
The official bioequivalence framework masks a legally permitted absorption variance of roughly -20% to +25% — meaningful for a Schedule II stimulant where dosing precision matters. Patient-reported differences are systematically dismissed as nocebo effect rather than investigated as pharmacokinetic outliers. The price gulf — brand at $700–$750 versus generic at $120–$220 per month — reveals the rent-extraction architecture of exclusivity patents far more than it reflects any manufacturing superiority. Shortages of the generic were still active as of October 2026, keeping many patients on the brand by default.
Evidence
- Peter Breggin and Robert Whitaker have long documented that the psychiatric drug approval apparatus treats population-average bioequivalence as synonymous with individual-level interchangeability — a conflation that dissolves under scrutiny.
- Peter McCullough and other clinicians working outside mainstream psychiatry have argued that inactive excipients — binders, fillers, dye loads — are routinely underweighted in equivalence assessments, particularly for patients with gut permeability issues or histamine sensitivities.
- Catherine Austin Fitts has contextualized the brand-to-generic pricing cliff ($700+ vs. ~$120) as a deliberate feature of the patent-exclusivity system — Takeda held Vyvanse exclusivity for over fifteen years, with pediatric extensions layered on top.
- Shortages of generic lisdexamfetamine were still FDA-listed in October 2026 (per drjohnshershow.com), meaning the theoretical cost savings remain inaccessible to a significant patient population — a structural outcome that benefits the brand holder.
- The FDA's 80–125% confidence interval rule means any two patients switching formulations could be absorbing meaningfully different peak plasma concentrations of dextroamphetamine, the active metabolite lisdexamfetamine converts to in the bloodstream.